<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">Parkinsons Dis</journal-id><journal-id journal-id-type="publisher-id">PD</journal-id><journal-title-group><journal-title>Parkinson's Disease</journal-title></journal-title-group><issn pub-type="ppub">2090-8083</issn><issn pub-type="epub">2042-0080</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5183770</article-id><article-id pub-id-type="doi">10.1155/2016/6734678</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Parkinson's Disease and Cognitive Impairment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6827-7944</contrib-id><name><surname>Yang</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Bei-sha</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3658-3928</contrib-id><name><surname>Guo</surname><given-names>Ji-feng</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China</aff><aff id="I2"><sup>2</sup>Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan 410008, China</aff><aff id="I3"><sup>3</sup>State Key Laboratory of Medical Genetics, Changsha, Hunan 410008, China</aff><aff id="I4"><sup>4</sup>Neurodegenerative Disorders Research Center, Central South University, Changsha, Hunan 410008, China</aff><author-notes><corresp id="cor1">*Ji-feng Guo: <email>guojifeng2003@163.com</email></corresp><fn fn-type="other"><p>Academic Editor: Yuan-Han Yang</p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>6734678</elocation-id><history><date date-type="received"><day>15</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Yang Yang et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Parkinson's disease (PD) is a progressive neurodegenerative disease primarily characterized by the hallmarks of motor symptoms, such as tremor, bradykinesia, rigidity, and postural instability. However, through clinical investigations in patients and experimental findings in animal models of Parkinson's disease for years, it is now well recognized that Parkinson's disease is more than just a motor-deficit disorder. The majority of Parkinson's disease patients suffer from nonmotor disabilities, for instance, cognitive impairment, autonomic dysfunction, sensory dysfunction, and sleep disorder. So far, anti-PD prescriptions and surgical treatments have been mainly focusing on motor dysfunctions, leaving cognitive impairment a marginal clinical field. Within the nonmotor symptoms, cognitive impairment is one of the most common and significant aspects of Parkinson's disease, and cognitive deficits such as dysexecutive syndrome and visuospatial disturbances could seriously affect the quality of life, reduce life expectancy, prolong the duration of hospitalization, and therefore increase burdens of caregiver and medical costs. In this review, we have done a retrospective study of the recent related researches on epidemiology, clinical manifestation and diagnosis, genetics, and potential treatment of cognitive deficits in Parkinson's disease, aiming to provide a summary of cognitive impairment in Parkinson's disease and make it easy for clinicians to tackle this challenging issue in their future practice.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>In developed countries, nearly one out of 100 people older than 60 years old are affected by Parkinson's disease [<xref rid="B1" ref-type="bibr">1</xref>]. Cognitive impairment in Parkinson's disease, characterized by predominant executive deficits, visuospatial dysfunction, and relatively unaffected memory, ranges from Parkinson's disease mild cognitive impairment (PD-MCI) to Parkinson's disease dementia (PDD), the former of which could only be detected by various means of comprehensive neuropsychological observations and normally does not affect the patients' daily operations whereas the latter hits more than one area of cognition and is severe enough to impair social or working functions. Moreover, longitudinal studies of long-term clinical investigations suggested that the majority of PD or PD-MCI patients develop dementia as disease deteriorates into the late stage [<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>], and Parkinson's disease dementia is a critically influential factor for the reduced life expectancy in patients with Parkinson's disease [<xref rid="B5" ref-type="bibr">5</xref>]. Movement disorder has long been addressed to be burdensome in Parkinson's disease and the development of relatively effective restoration of dopamine by pharmaceutical treatment also contributes to the success of management of motor symptoms, leaving the treatment of nonmotor deficits an unmet clinical need. Furthermore, the aggravation of cognitive disturbances might also be strongly predicted by neuropsychological testing in the early stage of disease with or without timely medical treatment [<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>].</p><p>In this review, we illustrate the demographic and clinical symptoms potentially assessed as risk factors for nonmotor deficits in Parkinson's disease and discuss the underlying mechanisms of these symptoms with evidence from genetic studies, with primary focus on the clinical manifestations and diagnosis supported by neuropsychology research, neuroimaging, pharmacology, and molecular genetics. At last, we probe into the clinical pharmacological and nonpharmacological management for Parkinson's disease patients in the light of its heterogeneous nature.</p></sec><sec id="sec2"><title>2. Epidemiology</title><p>PD is one of the most common neurodegenerative disorders, whose incidence is second only to Alzheimer disease. According to a 5-year follow-up study by Broeders and a Norwegian ParkWest study by Pedersen, 25% to 50% of patients with Parkinson disease develop PD-MCI or PDD or progress from PD-MCI to PDD within 5 years of diagnosis [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Studies that followed patients prospectively diagnosed PD with normal cognition and discovered the incidence of cognitive impairment are few till now. However, according to the available evidence, the progression of cognitive impairment was very common and comparatively quick. For instance, one study exhibited that the cumulative incidence of developing cognitive impairment was 8.5% within 1-year follow-up and up to 47.4% within 6-year follow-up [<xref rid="B11" ref-type="bibr">11</xref>]. In other studies, the incidence of cognitive impairments in PD patients varied from 48% to 60% by 12&#x02013;15 years of retrospective follow-up [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. In addition, the community-based studies indicated that 20&#x02013;35% of PD population would develop PD-MCI and up to 10% would develop PDD per year [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. Nonetheless, it is difficult to compare the results of all studies mentioned above, due to differences in sample sizes and statistical methods used. Furthermore, one designed study also clarified that the onset of dementia in PD patients is approximately 70-year-old no matter when the onset of PD is [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Not only does the incidence of cognitive impairment in PD patients vary, but also the risk factors for PD-MCI and PDD vary. Pigott et al. claimed that increased baseline Hoehn &#x00026; Yahr Scale score and Unified PD Rating Scale motor score, and decreased baseline Dementia Rating Scale (DRS-2) scores are powerful predictors of early cognitive deficits [<xref rid="B17" ref-type="bibr">17</xref>]. It is widely accepted that DRS-2 might be effective and adequate for predicting cognitive disturbance and could be used as a reference method to test comprehensive cognitive function [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec id="sec3"><title>3. Etiology</title><p>In this part, we mainly focus on the genetics of PD. 18 PD-specific chromosomal loci are named<italic> PARK</italic> and numbered chronologically, nine of which have been identified and confirmed by linkage analysis or exome sequencing [<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>]. Eight of these loci were identified by linkage analysis, functional candidate gene approach or GWAS studies, and are deemed as susceptibility loci as risk factors [<xref rid="B34" ref-type="bibr">34</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>]. And still one of them is supposed to be erroneous locus found to be identical with<italic> PARK1</italic> [<xref rid="B40" ref-type="bibr">40</xref>]. Within the nine confirmed disease-causing genes,<italic> SNCA</italic>,<italic> LRRK</italic>, and<italic> VPS35</italic> exhibit an autosomal dominant hereditary pattern while other six genes,<italic> Parkin</italic>,<italic> PINK1</italic>,<italic> DJ-1</italic>,<italic> ATP13A2</italic>,<italic> PLA2G6</italic>, and<italic> FBX07</italic>, display an autosomal recessive hereditary pattern. Besides, some other genes, such as<italic> GIGYF2</italic>, were reported to be susceptible to PD with specific variants in different ethnic populations [<xref rid="B41" ref-type="bibr">41</xref>]. The mutated genes involved in PD cause brain dysfunction through various molecular mechanisms, including disturbance of presynaptic vesicle recycling and dopamine transmission, toxicity from aggregation of mutant proteins, degeneration of dopaminergic axon in substantia nigra, instability or mislocation of certain kinases, overactivation of ubiquitin kinase activities, and decreased efficiencies of ubiquitin degradation pathways [<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>]. Although only 10&#x02013;15% of PD cases are familial and studies related to the pathogenic mechanisms on the confirmed disease-causing genes or susceptible loci of PD are far from being complete, the discovery of PD-related genes is a critical step for us to unravel the mysteries behind neurodegeneration in PD. Up to date, there is limited research specifically dedicated to the study of the relationship between the genetic classifications of PD and molecular mechanisms of cognitive impairment in PD. However, some negative results indicated some distinctive genetic features of cognitive decline in PD could be differentiated from other neurodegenerative disorders with cognitive disturbances [<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>]. Furthermore, the filamentous Lewy body formation could be observed in early onset of PDD carrying SNCA mutations and Dementia with Lewy bodies (DLB) [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B55" ref-type="bibr">55</xref>], and the aggregation of <italic>&#x003b1;</italic>-synuclein could be detected in substantia nigra as well as cortex in idiopathic PD patients, which suggests that the accumulation of <italic>&#x003b1;</italic>-synuclein could be the presynaptic dysfunction attributed to neuronal toxicity caused by various genetic or nongenetic risk factors. It is also found that the frequency of glucocerebrosidase mutations is increased in postmortem samples from PD patients who had positive <italic>&#x003b1;</italic>-synuclein inclusions [<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>], and the<italic> BDNF</italic> (Met/Met) homozygotes demonstrate dramatically worse cognitive impairment in PD patients compared to noncarriers [<xref rid="B58" ref-type="bibr">58</xref>].</p></sec><sec id="sec4"><title>4. Clinical Characteristics and Diagnosis</title><p>There is dramatic heterogeneity in clinical definition and correlation of cognitive impairment in PD, ranging from mild cognitive impairment to dementia [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>]. It has been a long time that the definition and characteristics of PD-MCI and PDD exist as a controversial issue, until the Movement Disorder Society (MDS) took the initiative to conduct a Task Force to systematically review the most representative literatures. They evaluated the incidences and characteristics of PD-MCI, as well as its relationship with dementia and its inclination of progressing to dementia [<xref rid="B61" ref-type="bibr">61</xref>]. For PD-MCI, the Movement Disorder Society (MDS) finally selected a total of 8 articles (6 cross-sectional studies and 2 longitudinal studies) from 1156 articles (874 for Parkinson &#x00026; cognitive impairment and 172 for Parkinson &#x00026; MCI) [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B62" ref-type="bibr">62</xref>&#x02013;<xref rid="B67" ref-type="bibr">67</xref>], in which the study design, population studied, methodology for statistical analysis, and criteria for PD-MCI/PDD definition vary considerably. On the other hand, publications related to PDD are much more available than those to PD-MCI. The MDS also reviewed the previous publications of dementia in PD excluding the cases of Dementia with Lewy Bodies (DLB) in terms of the &#x0201c;1-year rule,&#x0201d; characterized the clinical manifestations, and used these results to illustrate the criteria of probable and possible PDD based on the consensus from experts [<xref rid="B68" ref-type="bibr">68</xref>].</p><p>The criteria of both PD-MCI and PDD are defined by clinical, cognitive, and functional aspects. As more time and effort have been devoted to the study of PDD, the criteria for PDD were established first, which also profoundly influenced the proposed criteria for PD-MCI [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>]. Similar to the practicality of diagnosis in PDD criteria, a two-level operational schema on the thorough basis of neuropsychological testing is also applied in PD-MCI criteria [<xref rid="B69" ref-type="bibr">69</xref>]. Level I is a practical set which could be utilized easily by physicians and needs no neuropsychological testing from neurological or psychological experts, whereas Level II is documented in much more detail and is more favorable for researchers to conduct longitudinal studies.</p><p>In a brief assessment of Level I, clinical diagnosis of PD based on Queen's Square Brain Bank criteria for PD must be established for both PD-MCI and PDD [<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>]. For PD-MCI, cognitive capability is declined slowly which might be described by caregivers or patients or observed by clinicians from testing results. On the other hand, cognitive impairment caused by the clinical manifestations of parkinsonism other than idiopathic PD, other primary possibilities for cognitive disturbances, and other PD-associated comorbid circumstances that could significantly influence the outcome of cognitive testing should be excluded from PD-MCI [<xref rid="B68" ref-type="bibr">68</xref>]. The most important point to differentiate PDD from DLB is that PD symptoms should develop prior to the onset of dementia, which could be obtained by clinicians, gathered from the patient him/herself, informant or follow-up records/past medical history [<xref rid="B69" ref-type="bibr">69</xref>]. As PD-MCI is a prestage of PDD and progresses to PDD in most cases, the cognitive deficits scaled by a global cognitive ability test or at least two of neuropsychological tests for the five cognitive domains (to erase the limitation of a single neuropsychological test) in PD-MCI should be subtle on complex functional task and not be sufficient to interfere significantly with functional independence [<xref rid="B68" ref-type="bibr">68</xref>]. However, the cognitive impairment, which can be examined by global cognitive ability tests (e.g., MMSE below 26 [<xref rid="B72" ref-type="bibr">72</xref>]) and by at least two of the neuropsychological tests (months reversed [<xref rid="B73" ref-type="bibr">73</xref>] or seven backward [<xref rid="B72" ref-type="bibr">72</xref>], lexical fluency or clock drawing [<xref rid="B74" ref-type="bibr">74</xref>], MMSE pentagons [<xref rid="B72" ref-type="bibr">72</xref>], and 3-word recall [<xref rid="B72" ref-type="bibr">72</xref>]), is supposed to be severe enough to impair daily living activities, which could be assessed by a list of simple tasks. And the cognitive impairment should be assessed without administration of antiparkinsonian drugs and not be attributed to other categories of abnormalities such as autonomic or motor symptoms caused by PDD [<xref rid="B69" ref-type="bibr">69</xref>].</p><p>Once the diagnosis of cognitive impairment, including PD-MCI or PDD, is established, specifying the subtypes of cognitive deficiency and evaluating the severity of disease are quite beneficial for research, clinical practicing and monitoring, and even standardized pharmacological interventions. For PD-MCI diagnosis by Level II criteria, at least two of neuropsychological tests examining each of the five cognitive domains are recommended by MDS. Performance of patients between 1 and 2 standard deviations (SD) below individual variation adjustment showing predominant impairment or premorbid levels may be demonstrated in PD-MCI. But patients within 1 SD below normalization tested by a serial of neuropsychological measurements or who reported significantly cognitive decline over time are also accredited to diagnose PD-MCI [<xref rid="B75" ref-type="bibr">75</xref>]. For PD-MCI subtyping, to differentiate PD-MCI as single or multiple domains, at least two neuropsychological tests in each cognitive domain should be conducted. Impaired performance of two tests in the same one cognitive domain without impairment in other cognitive domains demonstrates the single-domain subtype. On the other hand, impaired performance of at least one test in no less than two cognitive domains indicates the multiple-domain type [<xref rid="B76" ref-type="bibr">76</xref>&#x02013;<xref rid="B91" ref-type="bibr">91</xref>]. However, for PDD Level II testing, assessments of severity using quantitative measurements do not have upper limit scores in diagnosis. The goal of Level II testing, for one thing, is to confirm the uncertain PDD diagnosis when the clinical manifestations of cognitive impairment are not obvious or relatively confused. It also serves to depict the individual characteristic of PDD and as an indicator of pharmacological responsiveness. In PDD, there are five cognitive domains involved in Level II testing: global cognitive efficiency, executive functions, memory, instrumental functions, and neuropsychiatric functions, in which executive functions and memory are classified as subcorticofrontal functions and instrumental functions are believed to be cortically mediated [<xref rid="B92" ref-type="bibr">92</xref>].</p></sec><sec id="sec5"><title>5. Treatment</title><p>Abnormal activities of various subtypes of neurons have been involved in the cognitive impairment of PD, including the dysregulation of dopaminergic, cholinergic, and probably glutamatergic or noradrenergic neurons [<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>].</p><p>Cholinesterase inhibitors, such as rivastigmine, have been proved beneficial to the improvement of global cognition and clinical manifestations as well as neuropsychiatric testing (especially for attention and executive functioning amelioration) by several large-scale multicenter randomized placebo-controlled trials [<xref rid="B95" ref-type="bibr">95</xref>&#x02013;<xref rid="B98" ref-type="bibr">98</xref>]. However, Donepezil, also a cholinesterase inhibitor, was not effective for global cognitive improvement or other neuropsychiatric symptoms in PD-MCI or PDD in a large randomized controlled study [<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>], although its beneficial effect was reported in some small placebo-controlled studies [<xref rid="B99" ref-type="bibr">99</xref>].</p><p>Partial NMDA-receptor antagonist has been used as a therapeutic option to treat PD patients with cognitive defects in several placebo-controlled trails [<xref rid="B101" ref-type="bibr">101</xref>&#x02013;<xref rid="B104" ref-type="bibr">104</xref>]. However, the results of studies were not consistent or notable; only one trial showed statistical differences in the improvement of global cognition [<xref rid="B102" ref-type="bibr">102</xref>], whereas most of trials suggested no pharmacological effects of partial NMDA-receptor antagonist on neuropsychiatric symptoms or improvement of daily life [<xref rid="B105" ref-type="bibr">105</xref>].</p><p>Atomoxetine, a noradrenergic reuptake inhibitor, and clozapine, an inhibitor of serotonin and dopamine receptors, as well as second-generation tricyclic antidepressant (TCA) nortriptyline and pramipexole, have been shown to be beneficial for the regulation of attention, psychosis, and depression, respectively, by evidence from several placebo-controlled trials [<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>].</p><p>Dysexecutive profile, which is known as the most predominant component of cognitive deficits in PD-MCI and PDD, has been substantiated to be improved with levodopa treatment [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B93" ref-type="bibr">93</xref>]. Levodopa was found to act on some aspects of cognition such as flexibility and working memory without beneficial changes of other functions like visuospatial recognition, verbal ability, or associative learning [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B93" ref-type="bibr">93</xref>]. For patients with nondopaminergic antiparkinsonian administration, antagonists of the NMDA-type glutamate receptor, amantadine, for instance, could slow down the progressive transition from PD-MCI to PDD, via increasing dopamine release and blocking dopamine reuptake [<xref rid="B109" ref-type="bibr">108</xref>].</p><p>Subthalamic deep brain stimulation, which is commonly conducted on PD patients with motor complications that are resistant to antiparkinsonian medication, was claimed to be harmful for semantic and verbal fluency as well as executive profiles by a meta-analysis [<xref rid="B110" ref-type="bibr">109</xref>]. In the meantime, this invasive procedure, with the possibility of causing damage to the vital brain regions in charge of advanced cognitive functions, has been related to significant exacerbation of dysexecutive profile that is not observed in most desirable pharmacological treatments [<xref rid="B111" ref-type="bibr">110</xref>].</p><p>Neuroprotective agents aiming to interrupt <italic>&#x003b1;</italic>-synuclein aggregation or to restore neuronal integrity are currently not available, whereas some cognitive interventions that are helpful in Alzheimer's disease have been identified to have positive results in the early stage of randomized clinical studies [<xref rid="B112" ref-type="bibr">111</xref>, <xref rid="B113" ref-type="bibr">112</xref>].</p><p>While deep brain stimulation (DBS) is effective for the motor deficits of Parkinson's disease (PD) that is well documented, cognitive and psychiatric benefits and side effects from the subthalamic nucleus (STN) and globus pallidus interna (GPi) DBS for PD are increasingly recognized. On one hand, it has been reported that DBS could significantly improve immediate verbal memory and reduce anxiety symptoms [<xref rid="B114" ref-type="bibr">113</xref>]; on the other hand, it is also investigated that certain types of impaired domain such as attention impairment predicted more detrimental results after DBS [<xref rid="B115" ref-type="bibr">114</xref>]. Therefore, the improvements of cognitive symptoms from DBS require further studies and warrant the precise cognitive tests that stratify the relative risks and benefits of surgery.</p></sec><sec id="sec6"><title>6. Conclusion</title><p>Cognitive impairment in PD, as in other neurodegenerative diseases, demonstrates the common role of neurodegeneration as well as the PD-featured damage in certain advanced cognitive brain regions accompanied with characterized clinical manifestations. The treatments for cognitive deficits in PD remain limited and inadequate since the disturbances of neuronal network involved in the process are still obscure and elusive. As the population ages, the increasing burden for both patients and caregivers from PD-MCI and PDD makes it urgent to approach to the pathogenic mechanisms and therapeutic targets of cognitive deficits in PD, as well as to research and develop novel pharmacological treatments and other interventions that could potentially be used in PD cognitive impairment.</p></sec></body><back><sec sec-type="COI-statement"><title>Competing Interests</title><p>The authors declare that they have no competing interests.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litvan</surname><given-names>I.</given-names></name><name><surname>Bhatia</surname><given-names>K. P.</given-names></name><name><surname>Burn</surname><given-names>D. J.</given-names></name><etal/></person-group><article-title>SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders</article-title><source><italic>Movement Disorders</italic></source><year>2003</year><volume>18</volume><issue>5</issue><fpage>467</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1002/mds.10459</pub-id><pub-id pub-id-type="other">2-s2.0-0038147327</pub-id><pub-id pub-id-type="other">12722160</pub-id><?supplied-pmid 12722160?><pub-id pub-id-type="pmid">12722160</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buter</surname><given-names>T. C.</given-names></name><name><surname>van den Hout</surname><given-names>A.</given-names></name><name><surname>Matthews</surname><given-names>F. E.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Brayne</surname><given-names>C.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name></person-group><article-title>Dementia and survival in Parkinson disease: a 12-year population study</article-title><source><italic>Neurology</italic></source><year>2008</year><volume>70</volume><issue>13</issue><fpage>1017</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000306632.43729.24</pub-id><pub-id pub-id-type="other">2-s2.0-41349114646</pub-id><pub-id pub-id-type="pmid">18362281</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hely</surname><given-names>M. A.</given-names></name><name><surname>Reid</surname><given-names>W. G. J.</given-names></name><name><surname>Adena</surname><given-names>M. A.</given-names></name><name><surname>Halliday</surname><given-names>G. M.</given-names></name><name><surname>Morris</surname><given-names>J. G. L.</given-names></name></person-group><article-title>The Sydney multicenter study of Parkinson&#x02019;s disease: the inevitability of dementia at 20 years</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>6</issue><fpage>837</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1002/mds.21956</pub-id><pub-id pub-id-type="other">2-s2.0-41149173996</pub-id><pub-id pub-id-type="pmid">18307261</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Andersen</surname><given-names>K.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Lolk</surname><given-names>A.</given-names></name><name><surname>Kragh-S&#x000f8;rensen</surname><given-names>P.</given-names></name></person-group><article-title>Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study</article-title><source><italic>Archives of Neurology</italic></source><year>2003</year><volume>60</volume><issue>3</issue><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1001/archneur.60.3.387</pub-id><pub-id pub-id-type="other">2-s2.0-0037335814</pub-id><pub-id pub-id-type="pmid">12633150</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>G.</given-names></name><name><surname>Tang</surname><given-names>M.-X.</given-names></name><name><surname>Louis</surname><given-names>E. D.</given-names></name><etal/></person-group><article-title>The association of incident dementia with mortality in PD</article-title><source><italic>Neurology</italic></source><year>2002</year><volume>59</volume><issue>11</issue><fpage>1708</fpage><lpage>1713</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000036610.36834.E0</pub-id><pub-id pub-id-type="other">2-s2.0-0037058779</pub-id><pub-id pub-id-type="other">12473757</pub-id><?supplied-pmid 12473757?><pub-id pub-id-type="pmid">12473757</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D.</given-names></name><name><surname>Mavandadi</surname><given-names>S.</given-names></name><name><surname>Mamikonyan</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2010</year><volume>75</volume><issue>5</issue><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ebdd79</pub-id><pub-id pub-id-type="other">2-s2.0-77955404787</pub-id><pub-id pub-id-type="other">20679638</pub-id><?supplied-pmid 20679638?><pub-id pub-id-type="pmid">20679638</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinforiani</surname><given-names>E.</given-names></name><name><surname>Banchieri</surname><given-names>L.</given-names></name><name><surname>Zucchella</surname><given-names>C.</given-names></name><name><surname>Pacchetti</surname><given-names>C.</given-names></name><name><surname>Sandrini</surname><given-names>G.</given-names></name></person-group><article-title>Cognitive rehabilitation in Parkinson's disease</article-title><source><italic>Archives of gerontology and geriatrics. Supplement</italic></source><year>2004</year><issue>9</issue><fpage>387</fpage><lpage>391</lpage><pub-id pub-id-type="other">2-s2.0-5444271895</pub-id><pub-id pub-id-type="pmid">15207437</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Par&#x000ed;s</surname><given-names>A. P.</given-names></name><name><surname>Saleta</surname><given-names>H. G.</given-names></name><name><surname>de la Cruz Crespo Maraver</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>7</issue><fpage>1251</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1002/mds.23688</pub-id><pub-id pub-id-type="other">2-s2.0-79959350034</pub-id><pub-id pub-id-type="other">21442659</pub-id><?supplied-pmid 21442659?><pub-id pub-id-type="pmid">21442659</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broeders</surname><given-names>M.</given-names></name><name><surname>Velseboer</surname><given-names>D. C.</given-names></name><name><surname>de Bie</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study</article-title><source><italic>Journal of the International Neuropsychological Society</italic></source><year>2013</year><volume>19</volume><issue>6</issue><fpage>695</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1017/s1355617713000295</pub-id><pub-id pub-id-type="other">2-s2.0-84880457823</pub-id><pub-id pub-id-type="pmid">23544964</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>K. F.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Tysnes</surname><given-names>O.-B.</given-names></name><name><surname>Alves</surname><given-names>G.</given-names></name></person-group><article-title>Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study</article-title><source><italic>JAMA Neurology</italic></source><year>2013</year><volume>70</volume><issue>5</issue><fpage>580</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2013.2110</pub-id><pub-id pub-id-type="other">2-s2.0-84877748982</pub-id><pub-id pub-id-type="pmid">23529397</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershey</surname><given-names>L. A.</given-names></name><name><surname>Peavy</surname><given-names>G. M.</given-names></name></person-group><article-title>Cognitive decline in Parkinson disease: how steep and crowded is the slope?</article-title><source><italic>Neurology</italic></source><year>2015</year><volume>85</volume><issue>15</issue><fpage>1268</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000002003</pub-id><pub-id pub-id-type="other">2-s2.0-84944415279</pub-id><pub-id pub-id-type="pmid">26362284</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hely</surname><given-names>M. A.</given-names></name><name><surname>Morris</surname><given-names>J. G. L.</given-names></name><name><surname>Reid</surname><given-names>W. G. J.</given-names></name><name><surname>Trafficante</surname><given-names>R.</given-names></name></person-group><article-title>Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years</article-title><source><italic>Movement Disorders</italic></source><year>2005</year><volume>20</volume><issue>2</issue><fpage>190</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1002/mds.20324</pub-id><pub-id pub-id-type="other">2-s2.0-14944354884</pub-id><pub-id pub-id-type="pmid">15551331</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buter</surname><given-names>T. C.</given-names></name><name><surname>Van Den Hout</surname><given-names>A.</given-names></name><name><surname>Matthews</surname><given-names>F. E.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Brayne</surname><given-names>C.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name></person-group><article-title>Dementia and survival in Parkinson disease: A 12-year Population Study</article-title><source><italic>Neurology</italic></source><year>2008</year><volume>70</volume><issue>13</issue><fpage>1017</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000306632.43729.24</pub-id><pub-id pub-id-type="other">2-s2.0-41349114646</pub-id><pub-id pub-id-type="pmid">18362281</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Andersen</surname><given-names>K.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Lolk</surname><given-names>A.</given-names></name><name><surname>Nielsen</surname><given-names>H.</given-names></name><name><surname>Kragh-S&#x000f8;rensen</surname><given-names>P.</given-names></name></person-group><article-title>Risk of dementia in Parkinson's disease: a community-based, prospective study</article-title><source><italic>Neurology</italic></source><year>2001</year><volume>56</volume><issue>6</issue><fpage>730</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1212/wnl.56.6.730</pub-id><pub-id pub-id-type="other">2-s2.0-0035957311</pub-id><pub-id pub-id-type="pmid">11274306</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>P.</given-names></name><name><surname>Gallacher</surname><given-names>J.</given-names></name><name><surname>Meara</surname><given-names>J.</given-names></name></person-group><article-title>Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom</article-title><source><italic>Movement Disorders</italic></source><year>2005</year><volume>20</volume><issue>8</issue><fpage>995</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1002/mds.20489</pub-id><pub-id pub-id-type="other">2-s2.0-26444511229</pub-id><pub-id pub-id-type="other">15852368</pub-id><?supplied-pmid 15852368?><pub-id pub-id-type="pmid">15852368</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>W. G. J.</given-names></name><name><surname>Hely</surname><given-names>M. A.</given-names></name><name><surname>Morris</surname><given-names>J. G. L.</given-names></name><name><surname>Loy</surname><given-names>C.</given-names></name><name><surname>Halliday</surname><given-names>G. M.</given-names></name></person-group><article-title>Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study)</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>2011</year><volume>82</volume><issue>9</issue><fpage>1033</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2010.232678</pub-id><pub-id pub-id-type="other">2-s2.0-80051552956</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pigott</surname><given-names>K.</given-names></name><name><surname>Rick</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>S. X.</given-names></name><etal/></person-group><article-title>Longitudinal study of normal cognition in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2015</year><volume>85</volume><issue>15</issue><fpage>1276</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002001</pub-id><pub-id pub-id-type="other">2-s2.0-84944383247</pub-id><pub-id pub-id-type="pmid">26362285</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Bronnick</surname><given-names>K.</given-names></name><name><surname>Williams-Gray</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis</article-title><source><italic>Neurology</italic></source><year>2010</year><volume>75</volume><issue>12</issue><fpage>1062</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1212/wnl.0b013e3181f39d0e</pub-id><pub-id pub-id-type="other">2-s2.0-77957233081</pub-id><pub-id pub-id-type="pmid">20855849</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname><given-names>J. H.</given-names></name><name><surname>Maraganore</surname><given-names>D. M.</given-names></name><name><surname>Peterson</surname><given-names>B. J.</given-names></name><name><surname>McDonnell</surname><given-names>S. K.</given-names></name><name><surname>Ahlskog</surname><given-names>J. E.</given-names></name><name><surname>Rocca</surname><given-names>W. A.</given-names></name></person-group><article-title>Head trauma preceding PD: A Case-control Study</article-title><source><italic>Neurology</italic></source><year>2003</year><volume>60</volume><issue>10</issue><fpage>1610</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000068008.78394.2c</pub-id><pub-id pub-id-type="other">2-s2.0-0038137236</pub-id><pub-id pub-id-type="pmid">12771250</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H.</given-names></name><name><surname>Braak</surname><given-names>E.</given-names></name></person-group><article-title>Pathoanatomy of Parkinson's disease</article-title><source><italic>Journal of Neurology, Supplement</italic></source><year>2000</year><volume>247</volume><issue>2</issue><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s004150050002</pub-id><pub-id pub-id-type="other">2-s2.0-0034007822</pub-id><pub-id pub-id-type="other">10991663</pub-id><?supplied-pmid 10991663?><pub-id pub-id-type="pmid">10991663</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fonzo</surname><given-names>A.</given-names></name><name><surname>Dekker</surname><given-names>M. C. J.</given-names></name><name><surname>Montagna</surname><given-names>P.</given-names></name><etal/></person-group><article-title>FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>72</volume><issue>3</issue><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000338144.10967.2b</pub-id><pub-id pub-id-type="other">2-s2.0-59649088353</pub-id><pub-id pub-id-type="pmid">19038853</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fonzo</surname><given-names>A.</given-names></name><name><surname>Roh&#x000e9;</surname><given-names>C. F.</given-names></name><name><surname>Ferreira</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease</article-title><source><italic>Lancet</italic></source><year>2005</year><volume>365</volume><issue>9457</issue><fpage>412</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)17829-5</pub-id><pub-id pub-id-type="other">2-s2.0-19944431081</pub-id><pub-id pub-id-type="other">15680456</pub-id><?supplied-pmid 15680456?><pub-id pub-id-type="pmid">15680456</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbaz</surname><given-names>A.</given-names></name><name><surname>Bower</surname><given-names>J. H.</given-names></name><name><surname>Maraganore</surname><given-names>D. M.</given-names></name><etal/></person-group><article-title>Risk tables for parkinsonism and Parkinson's disease</article-title><source><italic>Journal of Clinical Epidemiology</italic></source><year>2002</year><volume>55</volume><issue>1</issue><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(01)00425-5</pub-id><pub-id pub-id-type="other">2-s2.0-0036137526</pub-id><pub-id pub-id-type="other">11781119</pub-id><?supplied-pmid 11781119?><pub-id pub-id-type="pmid">11781119</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrer</surname><given-names>M.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Lewy bodies and parkinsonism in families with parkin mutations</article-title><source><italic>Annals of Neurology</italic></source><year>2001</year><volume>50</volume><issue>3</issue><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1002/ana.1132</pub-id><pub-id pub-id-type="other">2-s2.0-0034848395</pub-id><pub-id pub-id-type="other">11558785</pub-id><?supplied-pmid 11558785?><pub-id pub-id-type="pmid">11558785</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foroud</surname><given-names>T.</given-names></name><name><surname>Uniacke</surname><given-names>S. K.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2003</year><volume>60</volume><issue>5</issue><fpage>796</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000049470.00180.07</pub-id><pub-id pub-id-type="other">2-s2.0-12244262766</pub-id><pub-id pub-id-type="other">12629236</pub-id><?supplied-pmid 12629236?><pub-id pub-id-type="pmid">12629236</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>M.</given-names></name><name><surname>Hasegawa</surname><given-names>K.</given-names></name><name><surname>Kowa</surname><given-names>H.</given-names></name><name><surname>Saito</surname><given-names>M.</given-names></name><name><surname>Tsuji</surname><given-names>S.</given-names></name><name><surname>Obata</surname><given-names>F.</given-names></name></person-group><article-title>A new locus for Parkinson's Disease (PARK8) maps to chromosome 12p11.2-q13.1</article-title><source><italic>Annals of Neurology</italic></source><year>2002</year><volume>51</volume><issue>3</issue><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1002/ana.10113</pub-id><pub-id pub-id-type="other">2-s2.0-0036196860</pub-id><pub-id pub-id-type="other">11891824</pub-id><?supplied-pmid 11891824?><pub-id pub-id-type="pmid">11891824</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilks</surname><given-names>W. P.</given-names></name><name><surname>Abou-Sleiman</surname><given-names>P. M.</given-names></name><name><surname>Gandhi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A common LRRK2 mutation in idiopathic Parkinson's disease</article-title><source><italic>The Lancet</italic></source><year>2005</year><volume>365</volume><issue>9457</issue><fpage>415</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(05)17830-1</pub-id><pub-id pub-id-type="other">2-s2.0-19944432921</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldwurm</surname><given-names>S.</given-names></name><name><surname>Zini</surname><given-names>M.</given-names></name><name><surname>Mariani</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2007</year><volume>68</volume><issue>14</issue><fpage>1141</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000254483.19854.ef</pub-id><pub-id pub-id-type="other">2-s2.0-34147125812</pub-id><pub-id pub-id-type="pmid">17215492</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>D. G.</given-names></name><name><surname>Falchi</surname><given-names>M.</given-names></name><name><surname>O'Sullivan</surname><given-names>S. S.</given-names></name><etal/></person-group><article-title>Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study</article-title><source><italic>The Lancet Neurology</italic></source><year>2008</year><volume>7</volume><issue>7</issue><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70117-0</pub-id><pub-id pub-id-type="other">2-s2.0-50049104725</pub-id><pub-id pub-id-type="other">18539534</pub-id><?supplied-pmid 18539534?><pub-id pub-id-type="pmid">18539534</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>A. J.</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y.</given-names></name><name><surname>Daniel</surname><given-names>S. E.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name></person-group><article-title>What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study</article-title><source><italic>Neurology</italic></source><year>2001</year><volume>57</volume><issue>10</issue><fpage>S34</fpage><lpage>S38</lpage><pub-id pub-id-type="other">2-s2.0-18744420049</pub-id><pub-id pub-id-type="pmid">11775598</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>A. J.</given-names></name><name><surname>Daniel</surname><given-names>S. E.</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name></person-group><article-title>The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service</article-title><source><italic>Brain</italic></source><year>2002</year><volume>125</volume><issue>4</issue><fpage>861</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1093/brain/awf080</pub-id><pub-id pub-id-type="other">2-s2.0-0036209085</pub-id><pub-id pub-id-type="other">11912118</pub-id><?supplied-pmid 11912118?><pub-id pub-id-type="pmid">11912118</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulihan</surname><given-names>M. M.</given-names></name><name><surname>Ishihara-Paul</surname><given-names>L.</given-names></name><name><surname>Kachergus</surname><given-names>J.</given-names></name><etal/></person-group><article-title>LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study</article-title><source><italic>The Lancet Neurology</italic></source><year>2008</year><volume>7</volume><issue>7</issue><fpage>591</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70116-9</pub-id><pub-id pub-id-type="other">2-s2.0-48849092336</pub-id><pub-id pub-id-type="other">18539535</pub-id><?supplied-pmid 18539535?><pub-id pub-id-type="pmid">18539535</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C.</given-names></name><name><surname>Lohmann-Hedrich</surname><given-names>K.</given-names></name><name><surname>Rogaeva</surname><given-names>E.</given-names></name><name><surname>Schlossmacher</surname><given-names>M. G.</given-names></name><name><surname>Lang</surname><given-names>A. E.</given-names></name></person-group><article-title>Deciphering the role of heterozygous mutations in genes associated with parkinsonism</article-title><source><italic>The Lancet Neurology</italic></source><year>2007</year><volume>6</volume><issue>7</issue><fpage>652</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(07)70174-6</pub-id><pub-id pub-id-type="other">2-s2.0-34250372427</pub-id><pub-id pub-id-type="pmid">17582365</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>A. A.</given-names></name><name><surname>P&#x000e9;tursson</surname><given-names>H.</given-names></name><name><surname>J&#x000f3;nsson</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A susceptibility gene for late-onset idiopathic Parkinson's disease</article-title><source><italic>Annals of Neurology</italic></source><year>2002</year><volume>52</volume><issue>5</issue><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1002/ana.10324</pub-id><pub-id pub-id-type="other">2-s2.0-0036830525</pub-id><pub-id pub-id-type="other">12402251</pub-id><?supplied-pmid 12402251?><pub-id pub-id-type="pmid">12402251</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannone</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>E.</given-names></name><name><surname>Laviola</surname><given-names>L.</given-names></name><name><surname>Giorgino</surname><given-names>F.</given-names></name><name><surname>Cleveland</surname><given-names>K. A.</given-names></name><name><surname>Smith</surname><given-names>R. J.</given-names></name></person-group><article-title>Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>34</issue><fpage>31564</fpage><lpage>31573</lpage><pub-id pub-id-type="doi">10.1074/jbc.M211572200</pub-id><pub-id pub-id-type="other">2-s2.0-0041355365</pub-id><pub-id pub-id-type="other">12771153</pub-id><?supplied-pmid 12771153?><pub-id pub-id-type="pmid">12771153</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>P. D.</given-names></name><name><surname>Crocker</surname><given-names>S. J.</given-names></name><name><surname>Jackson-Lewis</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2003</year><volume>100</volume><issue>23</issue><fpage>13650</fpage><lpage>13655</lpage><pub-id pub-id-type="doi">10.1073/pnas.2232515100</pub-id><pub-id pub-id-type="other">2-s2.0-0344823864</pub-id><pub-id pub-id-type="other">14595022</pub-id><?supplied-pmid 14595022?><pub-id pub-id-type="pmid">14595022</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>K. M.</given-names></name><name><surname>Martins</surname><given-names>L. M.</given-names></name><name><surname>Plun-Favreau</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease</article-title><source><italic>Human Molecular Genetics</italic></source><year>2005</year><volume>14</volume><issue>15</issue><fpage>2099</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi215</pub-id><pub-id pub-id-type="other">2-s2.0-25444498785</pub-id><pub-id pub-id-type="other">15961413</pub-id><?supplied-pmid 15961413?><pub-id pub-id-type="pmid">15961413</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim&#x000f3;n-S&#x000e1;nchez</surname><given-names>J.</given-names></name><name><surname>Schulte</surname><given-names>C.</given-names></name><name><surname>Bras</surname><given-names>J. M.</given-names></name><etal/></person-group><article-title>Genome-wide association study reveals genetic risk underlying Parkinson's disease</article-title><source><italic>Nature Genetics</italic></source><year>2009</year><volume>41</volume><issue>12</issue><fpage>1308</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1038/ng.487</pub-id><pub-id pub-id-type="other">2-s2.0-70549088602</pub-id><pub-id pub-id-type="other">19915575</pub-id><?supplied-pmid 19915575?><pub-id pub-id-type="pmid">19915575</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chartier-Harlin</surname><given-names>M.-C.</given-names></name><name><surname>Dachsel</surname><given-names>J. C.</given-names></name><name><surname>Vilari&#x000f1;o-G&#x000fc;ell</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Translation initiator EIF4G1 mutations in familial parkinson disease</article-title><source><italic>The American Journal of Human Genetics</italic></source><year>2011</year><volume>89</volume><issue>3</issue><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.08.009</pub-id><pub-id pub-id-type="other">2-s2.0-80052780004</pub-id><pub-id pub-id-type="pmid">21907011</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrerova</surname><given-names>N.</given-names></name><name><surname>Petrucelli</surname><given-names>L.</given-names></name><name><surname>Farrer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>
<italic>&#x003b1;</italic>-Synuclein shares physical and functional homology with 14-3-3 proteins</article-title><source><italic>Journal of Neuroscience</italic></source><year>1999</year><volume>19</volume><issue>14</issue><fpage>5782</fpage><lpage>5791</lpage><pub-id pub-id-type="other">2-s2.0-0033565874</pub-id><pub-id pub-id-type="other">10407019</pub-id><?supplied-pmid 10407019?><pub-id pub-id-type="pmid">10407019</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Q.-Y.</given-names></name><name><surname>Yu</surname><given-names>R.-H.</given-names></name><name><surname>Guo</surname><given-names>J.-F.</given-names></name><name><surname>Tang</surname><given-names>B.-S.</given-names></name><name><surname>Yan</surname><given-names>X.-X.</given-names></name></person-group><article-title>The contribution of GIGYF2 to Parkinson&#x02019;s disease: a meta-analysis</article-title><source><italic>Neurological Sciences</italic></source><year>2015</year><volume>36</volume><issue>11</issue><fpage>2073</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1007/s10072-015-2316-9</pub-id><pub-id pub-id-type="other">2-s2.0-84945472472</pub-id><pub-id pub-id-type="pmid">26152800</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>M. G.</given-names></name><name><surname>Schmidt</surname><given-names>M. L.</given-names></name><name><surname>Lee</surname><given-names>V. M.-Y.</given-names></name><name><surname>Trojanowski</surname><given-names>J. Q.</given-names></name><name><surname>Jakes</surname><given-names>R.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name></person-group><article-title>
<italic>&#x003b1;</italic>-synuclein in Lewy bodies [8]</article-title><source><italic>Nature</italic></source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/42166</pub-id><pub-id pub-id-type="other">2-s2.0-0030882856</pub-id><pub-id pub-id-type="pmid">9278044</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Outeiro</surname><given-names>T. F.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name></person-group><article-title>Yeast cells provide insight into alpha-synuclein biology and pathobiology</article-title><source><italic>Science</italic></source><year>2003</year><volume>302</volume><issue>5651</issue><fpage>1772</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1126/science.1090439</pub-id><pub-id pub-id-type="other">2-s2.0-0345189364</pub-id><pub-id pub-id-type="pmid">14657500</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cookson</surname><given-names>M. R.</given-names></name></person-group><article-title>The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</article-title><source><italic>Nature Reviews Neuroscience</italic></source><year>2010</year><volume>11</volume><issue>12</issue><fpage>791</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/nrn2935</pub-id><pub-id pub-id-type="other">2-s2.0-78649389313</pub-id><pub-id pub-id-type="other">21088684</pub-id><?supplied-pmid 21088684?><pub-id pub-id-type="pmid">21088684</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plun-Favreau</surname><given-names>H.</given-names></name><name><surname>Klupsch</surname><given-names>K.</given-names></name><name><surname>Moisoi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1</article-title><source><italic>Nature Cell Biology</italic></source><year>2007</year><volume>9</volume><issue>11</issue><fpage>1243</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1038/ncb1644</pub-id><pub-id pub-id-type="other">2-s2.0-35748935851</pub-id><pub-id pub-id-type="other">17906618</pub-id><?supplied-pmid 17906618?><pub-id pub-id-type="pmid">17906618</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>I. E.</given-names></name><name><surname>Dodson</surname><given-names>M. W.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>
<italic>Drosophila pink1</italic> is required for mitochondrial function and interacts genetically with <italic>parkin</italic>
</article-title><source><italic>Nature</italic></source><year>2006</year><volume>441</volume><issue>7097</issue><fpage>1162</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1038/nature04779</pub-id><pub-id pub-id-type="other">2-s2.0-33745589773</pub-id><pub-id pub-id-type="pmid">16672981</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schapira</surname><given-names>A. H.</given-names></name></person-group><article-title>Mitochondria in the aetiology and pathogenesis of Parkinson's disease</article-title><source><italic>The Lancet Neurology</italic></source><year>2008</year><volume>7</volume><issue>1</issue><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70327-7</pub-id><pub-id pub-id-type="other">2-s2.0-37049004489</pub-id><pub-id pub-id-type="other">18093566</pub-id><?supplied-pmid 18093566?><pub-id pub-id-type="pmid">18093566</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;cking</surname><given-names>C. B.</given-names></name><name><surname>D&#x000fc;rr</surname><given-names>A.</given-names></name><name><surname>Bonifati</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Association between early-onset Parkinson's disease and mutations in the parkin gene</article-title><source><italic>New England Journal of Medicine</italic></source><year>2000</year><volume>342</volume><issue>21</issue><fpage>1560</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005253422103</pub-id><pub-id pub-id-type="other">2-s2.0-0342368772</pub-id><pub-id pub-id-type="other">10824074</pub-id><?supplied-pmid 10824074?><pub-id pub-id-type="pmid">10824074</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>K. K. K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lim</surname><given-names>K. L.</given-names></name><etal/></person-group><article-title>Parkin ubiquitinates the <italic>&#x003b1;</italic>-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease</article-title><source><italic>Nature Medicine</italic></source><year>2001</year><volume>7</volume><issue>10</issue><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1038/nm1001-1144</pub-id><pub-id pub-id-type="other">2-s2.0-0034776095</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V.</given-names></name><name><surname>Rizzu</surname><given-names>P.</given-names></name><name><surname>Van Baren</surname><given-names>M. J.</given-names></name><etal/></person-group><article-title>Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism</article-title><source><italic>Science</italic></source><year>2003</year><volume>299</volume><issue>5604</issue><fpage>256</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1126/science.1077209</pub-id><pub-id pub-id-type="other">2-s2.0-0037428241</pub-id><pub-id pub-id-type="other">12446870</pub-id><?supplied-pmid 12446870?><pub-id pub-id-type="pmid">12446870</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Sleiman</surname><given-names>P. M.</given-names></name><name><surname>Healy</surname><given-names>D. G.</given-names></name><name><surname>Quinn</surname><given-names>N.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name><name><surname>Wood</surname><given-names>N. W.</given-names></name></person-group><article-title>The role of pathogenic DJ-1 mutations in Parkinson's disease</article-title><source><italic>Annals of Neurology</italic></source><year>2003</year><volume>54</volume><issue>3</issue><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1002/ana.10675</pub-id><pub-id pub-id-type="other">2-s2.0-0042232353</pub-id><pub-id pub-id-type="other">12953260</pub-id><?supplied-pmid 12953260?><pub-id pub-id-type="pmid">12953260</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandopadhyay</surname><given-names>R.</given-names></name><name><surname>Kingsbury</surname><given-names>A. E.</given-names></name><name><surname>Cookson</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease</article-title><source><italic>Brain</italic></source><year>2004</year><volume>127</volume><issue>2</issue><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1093/brain/awh054</pub-id><pub-id pub-id-type="other">2-s2.0-10744224738</pub-id><pub-id pub-id-type="pmid">14662519</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson' s disease with cognitive impairment in a Chinese population</article-title><source><italic>Scientific Reports</italic></source><year>2016</year><volume>6</volume><pub-id pub-id-type="publisher-id">19021</pub-id><pub-id pub-id-type="doi">10.1038/srep19021</pub-id><pub-id pub-id-type="other">2-s2.0-84956641025</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y. Q.</given-names></name><name><surname>Tang</surname><given-names>B. S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Relationship between Alzheimer's disease GWAS-linked top hits and risk of Parkinson's disease with or without cognitive decline: a Chinese population-based study</article-title><source><italic>Neurobiology of Aging</italic></source><year>2016</year><volume>39</volume><fpage>217.e9</fpage><lpage>217.e11</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.11.024</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>H.</given-names></name><name><surname>Lipkin</surname><given-names>L. E.</given-names></name><name><surname>Aronson</surname><given-names>S. M.</given-names></name></person-group><article-title>Diffuse intracytoplasmic ganglionic inclusions (lewy type) associated with progressive dementia and quadriparesis in flexion</article-title><source><italic>Journal of Neuropathology and Experimental Neurology</italic></source><year>1961</year><volume>20</volume><issue>2</issue><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1097/00005072-196104000-00007</pub-id><pub-id pub-id-type="other">2-s2.0-0000443658</pub-id><pub-id pub-id-type="pmid">13730588</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J.</given-names></name><name><surname>Bras</surname><given-names>J.</given-names></name><name><surname>Deas</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease</article-title><source><italic>Brain</italic></source><year>2009</year><volume>132</volume><issue>7</issue><fpage>1783</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1093/brain/awp044</pub-id><pub-id pub-id-type="other">2-s2.0-67650087652</pub-id><pub-id pub-id-type="other">19286695</pub-id><?supplied-pmid 19286695?><pub-id pub-id-type="pmid">19286695</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidransky</surname><given-names>E.</given-names></name><name><surname>Nalls</surname><given-names>M. A.</given-names></name><name><surname>Aasly</surname><given-names>J. O.</given-names></name><etal/></person-group><article-title>Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease</article-title><source><italic>New England Journal of Medicine</italic></source><year>2009</year><volume>361</volume><issue>17</issue><fpage>1651</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0901281</pub-id><pub-id pub-id-type="other">2-s2.0-70350319531</pub-id><pub-id pub-id-type="other">19846850</pub-id><?supplied-pmid 19846850?><pub-id pub-id-type="pmid">19846850</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerini</surname><given-names>F. R.</given-names></name><name><surname>Beghi</surname><given-names>E.</given-names></name><name><surname>Riboldazzi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease</article-title><source><italic>European Journal of Neurology</italic></source><year>2009</year><volume>16</volume><issue>11</issue><fpage>1240</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02706.x</pub-id><pub-id pub-id-type="other">2-s2.0-70350134497</pub-id><pub-id pub-id-type="other">19538209</pub-id><?supplied-pmid 19538209?><pub-id pub-id-type="pmid">19538209</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litvan</surname><given-names>I.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Adler</surname><given-names>C. H.</given-names></name><etal/></person-group><article-title>MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>10</issue><fpage>1814</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1002/mds.23823</pub-id><pub-id pub-id-type="other">2-s2.0-80052267232</pub-id><pub-id pub-id-type="pmid">21661055</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.-Q.</given-names></name><name><surname>Tang</surname><given-names>B.-S.</given-names></name><name><surname>Yan</surname><given-names>X.-X.</given-names></name><etal/></person-group><article-title>A neurophysiological profile in Parkinson's disease with mild cognitive impairment and dementia in China</article-title><source><italic>Journal of Clinical Neuroscience</italic></source><year>2015</year><volume>22</volume><issue>6</issue><fpage>981</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2014.11.030</pub-id><pub-id pub-id-type="other">2-s2.0-84928938488</pub-id><pub-id pub-id-type="pmid">25890772</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muslimovi&#x00107;</surname><given-names>D.</given-names></name><name><surname>Post</surname><given-names>B.</given-names></name><name><surname>Speelman</surname><given-names>J. D.</given-names></name><name><surname>Schmand</surname><given-names>B.</given-names></name></person-group><article-title>Cognitive profile of patients with newly diagnosed Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2005</year><volume>65</volume><issue>8</issue><fpage>1239</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000180516.69442.95</pub-id><pub-id pub-id-type="other">2-s2.0-27144549543</pub-id><pub-id pub-id-type="other">16247051</pub-id><?supplied-pmid 16247051?><pub-id pub-id-type="pmid">16247051</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foltynie</surname><given-names>T.</given-names></name><name><surname>Brayne</surname><given-names>C. E. G.</given-names></name><name><surname>Robbins</surname><given-names>T. W.</given-names></name><name><surname>Barker</surname><given-names>R. A.</given-names></name></person-group><article-title>The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN Study</article-title><source><italic>Brain</italic></source><year>2004</year><volume>127</volume><issue>3</issue><fpage>550</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1093/brain/awh067</pub-id><pub-id pub-id-type="other">2-s2.0-1542375990</pub-id><pub-id pub-id-type="pmid">14691062</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoops</surname><given-names>S.</given-names></name><name><surname>Nazem</surname><given-names>S.</given-names></name><name><surname>Siderowf</surname><given-names>A. D.</given-names></name><etal/></person-group><article-title>Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>73</volume><issue>21</issue><fpage>1738</fpage><lpage>1745</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c34b47</pub-id><pub-id pub-id-type="other">2-s2.0-73349120962</pub-id><pub-id pub-id-type="other">19933974</pub-id><?supplied-pmid 19933974?><pub-id pub-id-type="pmid">19933974</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamikonyan</surname><given-names>E.</given-names></name><name><surname>Moberg</surname><given-names>P. J.</given-names></name><name><surname>Siderowf</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2009</year><volume>15</volume><issue>3</issue><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2008.05.006</pub-id><pub-id pub-id-type="other">2-s2.0-60649107807</pub-id><pub-id pub-id-type="other">18595765</pub-id><?supplied-pmid 18595765?><pub-id pub-id-type="pmid">18595765</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>M.-C.</given-names></name><name><surname>Chan</surname><given-names>S.-H.</given-names></name></person-group><article-title>Education and cognitive decline in parkinson's disease: a study of 102 patients</article-title><source><italic>Acta Neurologica Scandinavica</italic></source><year>2001</year><volume>103</volume><issue>4</issue><fpage>243</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0404.2001.103004243.x</pub-id><pub-id pub-id-type="other">2-s2.0-0035047416</pub-id><pub-id pub-id-type="pmid">11328196</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janvin</surname><given-names>C. C.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Hugdahl</surname><given-names>K.</given-names></name></person-group><article-title>Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>9</issue><fpage>1343</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1002/mds.20974</pub-id><pub-id pub-id-type="other">2-s2.0-33750367778</pub-id><pub-id pub-id-type="pmid">16721732</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams-Gray</surname><given-names>C. H.</given-names></name><name><surname>Foltynie</surname><given-names>T.</given-names></name><name><surname>Brayne</surname><given-names>C. E. G.</given-names></name><name><surname>Robbins</surname><given-names>T. W.</given-names></name><name><surname>Barker</surname><given-names>R. A.</given-names></name></person-group><article-title>Evolution of cognitive dysfunction in an incident Parkinson's disease cohort</article-title><source><italic>Brain</italic></source><year>2007</year><volume>130</volume><issue>7</issue><fpage>1787</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1093/brain/awm111</pub-id><pub-id pub-id-type="other">2-s2.0-34447633928</pub-id><pub-id pub-id-type="other">17535834</pub-id><?supplied-pmid 17535834?><pub-id pub-id-type="pmid">17535834</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emre</surname><given-names>M.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Clinical diagnostic criteria for dementia associated with Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>12</issue><fpage>1689</fpage><lpage>1707</lpage><pub-id pub-id-type="doi">10.1002/mds.21507</pub-id><pub-id pub-id-type="other">2-s2.0-35348939603</pub-id><pub-id pub-id-type="other">17542011</pub-id><?supplied-pmid 17542011?><pub-id pub-id-type="pmid">17542011</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Burn</surname><given-names>D.</given-names></name><name><surname>Goetz</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Diagnostic procedures for parkinson's disease dementia: recommendations from the movement disorder society task force</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>16</issue><fpage>2314</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1002/mds.21844</pub-id><pub-id pub-id-type="other">2-s2.0-38549126646</pub-id><pub-id pub-id-type="pmid">18098298</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>W. R. G.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name></person-group><article-title>The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>1988</year><volume>51</volume><issue>6</issue><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1136/jnnp.51.6.745</pub-id><pub-id pub-id-type="other">2-s2.0-0023898945</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>A. J.</given-names></name><name><surname>Daniel</surname><given-names>S. E.</given-names></name><name><surname>Blankson</surname><given-names>S.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name></person-group><article-title>A clinicopathologic study of 100 cases of Parkinson's disease</article-title><source><italic>Archives of Neurology</italic></source><year>1993</year><volume>50</volume><issue>2</issue><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1001/archneur.1993.00540020018011</pub-id><pub-id pub-id-type="other">2-s2.0-0027465936</pub-id><pub-id pub-id-type="other">8431132</pub-id><?supplied-pmid 8431132?><pub-id pub-id-type="pmid">8431132</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>M. F.</given-names></name><name><surname>Folstein</surname><given-names>S. E.</given-names></name><name><surname>McHugh</surname><given-names>P. R.</given-names></name></person-group><article-title>&#x0201c;Mini-mental state&#x0201d;. A practical method for grading the cognitive state of patients for the clinician</article-title><source><italic>Journal of Psychiatric Research</italic></source><year>1975</year><volume>12</volume><issue>3</issue><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="other">2-s2.0-0016823810</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shum</surname><given-names>D. H. K.</given-names></name><name><surname>McFarland</surname><given-names>K. A.</given-names></name><name><surname>Bain</surname><given-names>J. D.</given-names></name></person-group><article-title>Construct validity of eight tests of attention: comparison of normal and closed head injured samples</article-title><source><italic>Clinical Neuropsychologist</italic></source><year>1990</year><volume>4</volume><issue>2</issue><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1080/13854049008401508</pub-id><pub-id pub-id-type="other">2-s2.0-0025099935</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunderland</surname><given-names>T.</given-names></name><name><surname>Hill</surname><given-names>J. L.</given-names></name><name><surname>Mellow</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Clock drawing in Alzheimer's disease: a novel measure of dementia severity</article-title><source><italic>Journal of the American Geriatrics Society</italic></source><year>1989</year><volume>37</volume><issue>8</issue><fpage>725</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1989.tb02233.x</pub-id><pub-id pub-id-type="other">2-s2.0-0024372106</pub-id><pub-id pub-id-type="pmid">2754157</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>N. S.</given-names></name><name><surname>Truax</surname><given-names>P.</given-names></name></person-group><article-title>Clinical significance: a statistical approach to defining meaningful change in psychotherapy research</article-title><source><italic>Journal of Consulting and Clinical Psychology</italic></source><year>1991</year><volume>59</volume><issue>1</issue><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1037//0022-006x.59.1.12</pub-id><pub-id pub-id-type="other">2-s2.0-0026081811</pub-id><pub-id pub-id-type="pmid">2002127</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillon</surname><given-names>B.</given-names></name><name><surname>Deweer</surname><given-names>B.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name><name><surname>Dubois</surname><given-names>B.</given-names></name></person-group><article-title>Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases</article-title><source><italic>Archives of Neurology</italic></source><year>1993</year><volume>50</volume><issue>4</issue><fpage>374</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1001/archneur.1993.00540040036010</pub-id><pub-id pub-id-type="other">2-s2.0-0027474471</pub-id><pub-id pub-id-type="other">8460958</pub-id><?supplied-pmid 8460958?><pub-id pub-id-type="pmid">8460958</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D.</given-names></name><name><surname>Oehlberg</surname><given-names>K. A.</given-names></name><name><surname>Katz</surname><given-names>I. R.</given-names></name><name><surname>Stern</surname><given-names>M. B.</given-names></name></person-group><article-title>Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease</article-title><source><italic>The American Journal of Geriatric Psychiatry</italic></source><year>2006</year><volume>14</volume><issue>2</issue><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1097/01.jgp.0000192488.66049.4b</pub-id><pub-id pub-id-type="other">2-s2.0-32444435164</pub-id><pub-id pub-id-type="pmid">16473982</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>A. M.</given-names></name><name><surname>Beksinska</surname><given-names>M.</given-names></name><name><surname>James</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Visuospatial memory deficits at different stages of Parkinson's disease</article-title><source><italic>Neuropsychologia</italic></source><year>1993</year><volume>31</volume><issue>7</issue><fpage>627</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/0028-3932(93)90135-M</pub-id><pub-id pub-id-type="other">2-s2.0-0027161183</pub-id><pub-id pub-id-type="other">8371837</pub-id><?supplied-pmid 8371837?><pub-id pub-id-type="pmid">8371837</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>J. A.</given-names></name><name><surname>Sagar</surname><given-names>H. J.</given-names></name><name><surname>Jordan</surname><given-names>N.</given-names></name><name><surname>Harvey</surname><given-names>N. S.</given-names></name><name><surname>Sullivan</surname><given-names>E. V.</given-names></name></person-group><article-title>Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability</article-title><source><italic>Brain</italic></source><year>1991</year><volume>114</volume><issue>5</issue><fpage>2095</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1093/brain/114.5.2095</pub-id><pub-id pub-id-type="other">2-s2.0-0025993229</pub-id><pub-id pub-id-type="other">1933236</pub-id><?supplied-pmid 1933236?><pub-id pub-id-type="pmid">1933236</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flowers</surname><given-names>K. A.</given-names></name><name><surname>Robertson</surname><given-names>C.</given-names></name></person-group><article-title>The effect of Parkinson's disease on the ability to maintain a mental set</article-title><source><italic>Journal of Neurology Neurosurgery and Psychiatry</italic></source><year>1985</year><volume>48</volume><issue>6</issue><fpage>517</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1136/jnnp.48.6.517</pub-id><pub-id pub-id-type="other">2-s2.0-0021865532</pub-id><pub-id pub-id-type="other">4009189</pub-id><?supplied-pmid 4009189?><pub-id pub-id-type="pmid">4009189</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lhermitte</surname><given-names>F.</given-names></name><name><surname>Pillon</surname><given-names>B.</given-names></name><name><surname>Serdaru</surname><given-names>M.</given-names></name></person-group><article-title>Human autonomy and the frontal lobes. Part I: imitation and utilization behavior: a neuropsychological study of 75 patients</article-title><source><italic>Annals of Neurology</italic></source><year>1986</year><volume>19</volume><issue>4</issue><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1002/ana.410190404</pub-id><pub-id pub-id-type="other">2-s2.0-0022588692</pub-id><pub-id pub-id-type="pmid">3707084</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starkstein</surname><given-names>S. E.</given-names></name><name><surname>Mayberg</surname><given-names>H. S.</given-names></name><name><surname>Preziosi</surname><given-names>T. J.</given-names></name><name><surname>Andrezejewski</surname><given-names>P.</given-names></name><name><surname>Leiguarda</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>R. G.</given-names></name></person-group><article-title>Reliability, validity, and clinical correlates of apathy in Parkinson's disease</article-title><source><italic>Journal of Neuropsychiatry and Clinical Neurosciences</italic></source><year>1992</year><volume>4</volume><issue>2</issue><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1176/jnp.4.2.134</pub-id><pub-id pub-id-type="other">2-s2.0-0026569057</pub-id><pub-id pub-id-type="other">1627973</pub-id><?supplied-pmid 1627973?><pub-id pub-id-type="pmid">1627973</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J. L.</given-names></name><name><surname>Mega</surname><given-names>M.</given-names></name><name><surname>Gray</surname><given-names>K.</given-names></name><name><surname>Rosenberg-Thompson</surname><given-names>S.</given-names></name><name><surname>Carusi</surname><given-names>D. A.</given-names></name><name><surname>Gornbein</surname><given-names>J.</given-names></name></person-group><article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title><source><italic>Neurology</italic></source><year>1994</year><volume>44</volume><issue>12</issue><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1212/wnl.44.12.2308</pub-id><pub-id pub-id-type="other">2-s2.0-0027985334</pub-id><pub-id pub-id-type="pmid">7991117</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grober</surname><given-names>E.</given-names></name><name><surname>Buschke</surname><given-names>H.</given-names></name></person-group><article-title>Genuine memory deficits in dementia</article-title><source><italic>Developmental Neuropsychology</italic></source><year>1987</year><volume>3</volume><issue>1</issue><fpage>13</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1080/87565648709540361</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tierney</surname><given-names>M. C.</given-names></name><name><surname>Nores</surname><given-names>A.</given-names></name><name><surname>Snow</surname><given-names>W. G.</given-names></name><name><surname>Fisher</surname><given-names>R. H.</given-names></name><name><surname>Zorzitto</surname><given-names>M. L.</given-names></name><name><surname>Reid</surname><given-names>D. W.</given-names></name></person-group><article-title>Use of the Rey Auditory Verbal Learning Test in differentiating normal aging from Alzheimer's and Parkinson's dementia</article-title><source><italic>Psychological Assessment</italic></source><year>1994</year><volume>6</volume><issue>2</issue><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1037//1040-3590.6.2.129</pub-id><pub-id pub-id-type="other">2-s2.0-0028107922</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosimann</surname><given-names>U. P.</given-names></name><name><surname>Mather</surname><given-names>G.</given-names></name><name><surname>Wesnes</surname><given-names>K. A.</given-names></name><name><surname>O'Brien</surname><given-names>J. T.</given-names></name><name><surname>Burn</surname><given-names>D. J.</given-names></name><name><surname>McKeith</surname><given-names>I. G.</given-names></name></person-group><article-title>Visual perception in Parkinson disease dementia and dementia with Lewy bodies</article-title><source><italic>Neurology</italic></source><year>2004</year><volume>63</volume><issue>11</issue><fpage>2091</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000145764.70698.4E</pub-id><pub-id pub-id-type="other">2-s2.0-10444224025</pub-id><pub-id pub-id-type="other">15596755</pub-id><?supplied-pmid 15596755?><pub-id pub-id-type="pmid">15596755</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janvin</surname><given-names>C.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Larsen</surname><given-names>J. P.</given-names></name><name><surname>Hugdahl</surname><given-names>K.</given-names></name></person-group><article-title>Neuropsychological profile of patients with Parkinson's disease without dementia</article-title><source><italic>Dementia and Geriatric Cognitive Disorders</italic></source><year>2003</year><volume>15</volume><issue>3</issue><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1159/000068483</pub-id><pub-id pub-id-type="other">2-s2.0-0037279168</pub-id><pub-id pub-id-type="other">12584427</pub-id><?supplied-pmid 12584427?><pub-id pub-id-type="pmid">12584427</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benton</surname><given-names>A. L.</given-names></name><name><surname>Eslinger</surname><given-names>P. J.</given-names></name><name><surname>Damasio</surname><given-names>A. R.</given-names></name></person-group><article-title>Normative observations on neuropsychological test performances in old age</article-title><source><italic>Journal of Clinical Neuropsychology</italic></source><year>1981</year><volume>3</volume><issue>1</issue><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/01688638108403111</pub-id><pub-id pub-id-type="other">2-s2.0-0019499414</pub-id><pub-id pub-id-type="other">7276195</pub-id><?supplied-pmid 7276195?><pub-id pub-id-type="pmid">7276195</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Br&#x000f8;nnick</surname><given-names>K.</given-names></name><name><surname>Ehrt</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>2007</year><volume>78</volume><issue>1</issue><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2005.083113</pub-id><pub-id pub-id-type="other">2-s2.0-33846016934</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leentjens</surname><given-names>A. F. G.</given-names></name><name><surname>Verhey</surname><given-names>F. R. J.</given-names></name><name><surname>Lousberg</surname><given-names>R.</given-names></name><name><surname>Spitsbergen</surname><given-names>H.</given-names></name><name><surname>Wilmink</surname><given-names>F. W.</given-names></name></person-group><article-title>The validity of the Hamilton and Montgomery-&#x000c5;sberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease</article-title><source><italic>International Journal of Geriatric Psychiatry</italic></source><year>2000</year><volume>15</volume><issue>7</issue><fpage>644</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1002/1099-1166(200007)15:7&#x0003c;644::aid-gps167&#x0003e;3.0.co;2-l</pub-id><pub-id pub-id-type="other">2-s2.0-0033853816</pub-id><pub-id pub-id-type="pmid">10918346</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M.</given-names></name><name><surname>Leentjens</surname><given-names>A. F. G.</given-names></name><name><surname>Marinus</surname><given-names>J.</given-names></name><name><surname>Stiggelbout</surname><given-names>A. M.</given-names></name><name><surname>van Hilten</surname><given-names>J. J.</given-names></name></person-group><article-title>Reliability and validity of the Beck depression inventory in patients with Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>5</issue><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1002/mds.20792</pub-id><pub-id pub-id-type="other">2-s2.0-33646919491</pub-id><pub-id pub-id-type="pmid">16450355</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ertan</surname><given-names>F. S.</given-names></name><name><surname>Ertan</surname><given-names>T.</given-names></name><name><surname>Kiziltan</surname><given-names>G.</given-names></name><name><surname>Uygu&#x000e7;gil</surname><given-names>H.</given-names></name></person-group><article-title>Reliability and validity of the Geriatric Depression Scale in depression in Parkinson's disease</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>2005</year><volume>76</volume><issue>10</issue><fpage>1445</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2004.057984</pub-id><pub-id pub-id-type="other">2-s2.0-25444530613</pub-id><pub-id pub-id-type="other">16170093</pub-id><?supplied-pmid 16170093?><pub-id pub-id-type="pmid">16170093</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandstaedter</surname><given-names>D.</given-names></name><name><surname>Spieker</surname><given-names>S.</given-names></name><name><surname>Ulm</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Development and evaluation of the Parkinson Psychosis Questionnaire: a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease</article-title><source><italic>Journal of Neurology</italic></source><year>2005</year><volume>252</volume><issue>9</issue><fpage>1060</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1007/s00415-005-0816-x</pub-id><pub-id pub-id-type="other">2-s2.0-25144486661</pub-id><pub-id pub-id-type="pmid">15789127</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehagia</surname><given-names>A. A.</given-names></name><name><surname>Barker</surname><given-names>R. A.</given-names></name><name><surname>Robbins</surname><given-names>T. W.</given-names></name></person-group><article-title>Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease</article-title><source><italic>The Lancet Neurology</italic></source><year>2010</year><volume>9</volume><issue>12</issue><fpage>1200</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70212-X</pub-id><pub-id pub-id-type="other">2-s2.0-78349310514</pub-id><pub-id pub-id-type="other">20880750</pub-id><?supplied-pmid 20880750?><pub-id pub-id-type="pmid">20880750</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>J. C.</given-names></name><name><surname>Eggers</surname><given-names>C.</given-names></name><name><surname>Kalbe</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo</article-title><source><italic>Neurology</italic></source><year>2010</year><volume>74</volume><issue>11</issue><fpage>885</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181d55f61</pub-id><pub-id pub-id-type="other">2-s2.0-77950511411</pub-id><pub-id pub-id-type="other">20181924</pub-id><?supplied-pmid 20181924?><pub-id pub-id-type="pmid">20181924</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolinski</surname><given-names>M.</given-names></name><name><surname>Fox</surname><given-names>C.</given-names></name><name><surname>Maidment</surname><given-names>I.</given-names></name><name><surname>McShane</surname><given-names>R.</given-names></name></person-group><article-title>Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2012</year><volume>3</volume><pub-id pub-id-type="publisher-id">CD006504</pub-id><pub-id pub-id-type="other">2-s2.0-84861987193</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emre</surname><given-names>M.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Albanese</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Rivastigmine for dementia associated with Parkinson's disease</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2004</year><volume>351</volume><issue>24</issue><fpage>2509</fpage><lpage>2518</lpage><pub-id pub-id-type="doi">10.1056/nejmoa041470</pub-id><pub-id pub-id-type="other">2-s2.0-10044283107</pub-id><pub-id pub-id-type="pmid">15590953</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poewe</surname><given-names>W.</given-names></name><name><surname>Wolters</surname><given-names>E.</given-names></name><name><surname>Emre</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term benefits of rivastigmine in dementia associated with Parkinson's Disease: an active treatment extension study</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>4</issue><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/mds.20700</pub-id><pub-id pub-id-type="other">2-s2.0-33646256562</pub-id><pub-id pub-id-type="pmid">16229010</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>I.</given-names></name><name><surname>Del Ser</surname><given-names>T.</given-names></name><name><surname>Spano</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study</article-title><source><italic>The Lancet</italic></source><year>2000</year><volume>356</volume><issue>9247</issue><fpage>2031</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(00)03399-7</pub-id><pub-id pub-id-type="other">2-s2.0-0034676757</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Laar</surname><given-names>T.</given-names></name><name><surname>De Deyn</surname><given-names>P. P.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Barone</surname><given-names>P.</given-names></name><name><surname>Galvin</surname><given-names>J. E.</given-names></name></person-group><article-title>Effects of cholinesterase inhibitors in Parkinson&#x02019;s disease dementia: a review of clinical data</article-title><source><italic>CNS Neuroscience and Therapeutics</italic></source><year>2011</year><volume>17</volume><issue>5</issue><fpage>428</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00166.x</pub-id><pub-id pub-id-type="other">2-s2.0-80053217764</pub-id><pub-id pub-id-type="pmid">21951368</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Tolosa</surname><given-names>E.</given-names></name><name><surname>Kulisevsky</surname><given-names>J.</given-names></name><name><surname>Barone</surname><given-names>P.</given-names></name><name><surname>Galvin</surname><given-names>E. J.</given-names></name></person-group><article-title>Efficacy and safety of donepezil in the treatment of Parkinsons disease patients with dementia</article-title><conf-name>Proceedings of the 8th International Conference on Alzheimers and Parkinsons Diseases</conf-name><conf-date>2007</conf-date></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroi</surname><given-names>I.</given-names></name><name><surname>Overshott</surname><given-names>R.</given-names></name><name><surname>Byrne</surname><given-names>E. J.</given-names></name><name><surname>Daniel</surname><given-names>E.</given-names></name><name><surname>Burns</surname><given-names>A.</given-names></name></person-group><article-title>Randomized controlled trial of memantine in dementia associated with Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2009</year><volume>24</volume><issue>8</issue><fpage>1217</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1002/mds.22495</pub-id><pub-id pub-id-type="other">2-s2.0-67649406392</pub-id><pub-id pub-id-type="pmid">19370737</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Ballard</surname><given-names>C.</given-names></name><name><surname>Walker</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial</article-title><source><italic>The Lancet Neurology</italic></source><year>2009</year><volume>8</volume><issue>7</issue><fpage>613</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70146-2</pub-id><pub-id pub-id-type="other">2-s2.0-67649394221</pub-id><pub-id pub-id-type="other">19520613</pub-id><?supplied-pmid 19520613?><pub-id pub-id-type="pmid">19520613</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emre</surname><given-names>M.</given-names></name><name><surname>Tsolaki</surname><given-names>M.</given-names></name><name><surname>Bonuccelli</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial</article-title><source><italic>The Lancet Neurology</italic></source><year>2010</year><volume>9</volume><issue>10</issue><fpage>969</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(10)70194-0</pub-id><pub-id pub-id-type="other">2-s2.0-77956874908</pub-id><pub-id pub-id-type="pmid">20729148</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ondo</surname><given-names>W. G.</given-names></name><name><surname>Shinawi</surname><given-names>L.</given-names></name><name><surname>Davidson</surname><given-names>A.</given-names></name><name><surname>Lai</surname><given-names>D.</given-names></name></person-group><article-title>Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2011</year><volume>17</volume><issue>3</issue><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2010.12.003</pub-id><pub-id pub-id-type="other">2-s2.0-79951555963</pub-id><pub-id pub-id-type="pmid">21193343</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>V.</given-names></name><name><surname>Engedal</surname><given-names>K.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Wattmo</surname><given-names>C.</given-names></name><name><surname>Minthon</surname><given-names>L.</given-names></name><name><surname>Londos</surname><given-names>E.</given-names></name></person-group><article-title>Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson's disease dementia</article-title><source><italic>Dementia and Geriatric Cognitive Disorders</italic></source><year>2011</year><volume>32</volume><issue>4</issue><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1159/000334523</pub-id><pub-id pub-id-type="other">2-s2.0-82055175125</pub-id><pub-id pub-id-type="pmid">22122992</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seppi</surname><given-names>K.</given-names></name><name><surname>Weintraub</surname><given-names>D.</given-names></name><name><surname>Coelho</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26, supplement 3</volume><fpage>S42</fpage><lpage>S80</lpage><pub-id pub-id-type="doi">10.1002/mds.23884</pub-id><pub-id pub-id-type="other">2-s2.0-80051500137</pub-id><pub-id pub-id-type="pmid">22021174</pub-id></element-citation></ref><ref id="B109"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>J. A.</given-names></name><name><surname>Sagar</surname><given-names>H. J.</given-names></name><name><surname>Doherty</surname><given-names>S. M.</given-names></name><name><surname>Jordan</surname><given-names>N.</given-names></name><name><surname>Tidswell</surname><given-names>P.</given-names></name><name><surname>Sullivan</surname><given-names>E. V.</given-names></name></person-group><article-title>Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease follow-up study of untreated patients</article-title><source><italic>Brain</italic></source><year>1992</year><volume>115</volume><issue>6</issue><fpage>1701</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1093/brain/115.6.1701</pub-id><pub-id pub-id-type="other">2-s2.0-0027102421</pub-id><pub-id pub-id-type="pmid">1486457</pub-id></element-citation></ref><ref id="B110"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzelberg</surname><given-names>R.</given-names></name><name><surname>Bonuccelli</surname><given-names>U.</given-names></name><name><surname>Schechtman</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Association between amantadine and the onset of dementia in Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>9</issue><fpage>1375</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1002/mds.20968</pub-id><pub-id pub-id-type="other">2-s2.0-33750290651</pub-id><pub-id pub-id-type="other">16705684</pub-id><?supplied-pmid 16705684?><pub-id pub-id-type="pmid">16705684</pub-id></element-citation></ref><ref id="B111"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>K.</given-names></name><name><surname>Daniels</surname><given-names>C.</given-names></name><name><surname>Krack</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>2011</year><volume>310</volume><issue>1-2</issue><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2011.06.028</pub-id><pub-id pub-id-type="other">2-s2.0-80054097264</pub-id><pub-id pub-id-type="other">21733529</pub-id><?supplied-pmid 21733529?><pub-id pub-id-type="pmid">21733529</pub-id></element-citation></ref><ref id="B112"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>C.</given-names></name><name><surname>Krack</surname><given-names>P.</given-names></name><name><surname>Volkmann</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease</article-title><source><italic>Movement Disorders</italic></source><year>2010</year><volume>25</volume><issue>11</issue><fpage>1583</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1002/mds.23078</pub-id><pub-id pub-id-type="other">2-s2.0-77955822712</pub-id><pub-id pub-id-type="other">20589868</pub-id><?supplied-pmid 20589868?><pub-id pub-id-type="pmid">20589868</pub-id></element-citation></ref><ref id="B113"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;ckman</surname><given-names>L.</given-names></name><name><surname>Nyberg</surname><given-names>L.</given-names></name><name><surname>Soveri</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effects of working-memory training on striatal dopamine release</article-title><source><italic>Science</italic></source><year>2011</year><volume>333</volume><issue>6043</issue><pub-id pub-id-type="doi">10.1126/science.1204978</pub-id><pub-id pub-id-type="other">2-s2.0-84856455112</pub-id></element-citation></ref><ref id="B114"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>V.</given-names></name><name><surname>Zhu</surname><given-names>C. X. L.</given-names></name><name><surname>Chan</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Evidence of improved immediate verbal memory and diminished category fluency following STN-DBS in Chinese-Cantonese patients with idiopathic Parkinson's disease</article-title><source><italic>Neurological Sciences</italic></source><year>2015</year><volume>36</volume><issue>8</issue><fpage>1371</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1007/s10072-015-2117-1</pub-id><pub-id pub-id-type="other">2-s2.0-84938204673</pub-id><pub-id pub-id-type="pmid">25708249</pub-id></element-citation></ref><ref id="B115"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abboud</surname><given-names>H.</given-names></name><name><surname>Floden</surname><given-names>D.</given-names></name><name><surname>Thompson</surname><given-names>N. R.</given-names></name><etal/></person-group><article-title>Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's disease</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2015</year><volume>21</volume><issue>3</issue><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.12.018</pub-id><pub-id pub-id-type="other">2-s2.0-84923251188</pub-id><pub-id pub-id-type="other">25578289</pub-id><?supplied-pmid 25578289?><pub-id pub-id-type="pmid">25578289</pub-id></element-citation></ref></ref-list></back></article>